Balancing treatment, drug plan sustainability with ADHD in the workplace

Attention deficit hyperactivity disorder is a neurodevelopmental disorder, affecting up to nine per cent of children and five per cent of adults.

Read session coverage

Using drug plans to address women’s health at all life stages

Women face unique health challenges throughout their lives — across most age groups, women experience higher rates of chronic diseases compared to men.

This session was made possible by Pfizer Canada.

Read session coverage

The connection between drug benefits utilization and women’s health

Canada’s workforce increasingly reflects the unique health challenges faced by its female population.

Read session coverage

Precision oncology plays critical role in breast cancer treatment

Breast cancer is the most common cancer in Canada, predominantly affecting women, with more than 29,000 diagnoses in 2023.

This session was made possible by AstraZeneca Canada.

Read session coverage

Panel: A look at the evolution of drug coverage

Advances in medical science and innovations in drug development necessitate updated drug plan strategies.

This session was made possible by EMD Serono, GSK, iA Financial Group, Merck, Novo Nordisk Canada and Pfizer Canada.

Read session coverage

Employer-provided drug plans drive healthy, productive workplaces

Private drug plans play a pivotal role in ensuring faster and broader access to medications for 27 million Canadians.

Read session coverage